Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

Essential role of the linear ubiquitin chain assembly complex in lymphoma revealed by rare germline polymorphisms.

Yang Y, Schmitz R, Mitala J, Whiting A, Xiao W, Ceribelli M, Wright GW, Zhao H, Yang Y, Xu W, Rosenwald A, Ott G, Gascoyne RD, Connors JM, Rimsza LM, Campo E, Jaffe ES, Delabie J, Smeland EB, Braziel RM, Tubbs RR, Cook JR, Weisenburger DD, Chan WC, Wiestner A, Kruhlak MJ, Iwai K, Bernal F, Staudt LM.

Cancer Discov. 2014 Apr;4(4):480-93. doi: 10.1158/2159-8290.CD-13-0915. Epub 2014 Feb 3.

2.

Germline polymorphisms in RNF31 regulate linear ubiquitination and oncogenic signaling.

Grumati P, Dikic I.

Cancer Discov. 2014 Apr;4(4):394-6. doi: 10.1158/2159-8290.CD-14-0177.

3.

The paracaspase MALT1 cleaves the LUBAC subunit HOIL1 during antigen receptor signaling.

Douanne T, Gavard J, Bidère N.

J Cell Sci. 2016 May 1;129(9):1775-80. doi: 10.1242/jcs.185025. Epub 2016 Mar 22.

4.

Targeting Non-proteolytic Protein Ubiquitination for the Treatment of Diffuse Large B Cell Lymphoma.

Yang Y, Kelly P, Shaffer AL 3rd, Schmitz R, Yoo HM, Liu X, Huang DW, Webster D, Young RM, Nakagawa M, Ceribelli M, Wright GW, Yang Y, Zhao H, Yu X, Xu W, Chan WC, Jaffe ES, Gascoyne RD, Campo E, Rosenwald A, Ott G, Delabie J, Rimsza L, Staudt LM.

Cancer Cell. 2016 Apr 11;29(4):494-507. doi: 10.1016/j.ccell.2016.03.006.

5.

Inhibition of MALT1 protease activity is selectively toxic for activated B cell-like diffuse large B cell lymphoma cells.

Ferch U, Kloo B, Gewies A, Pfänder V, Düwel M, Peschel C, Krappmann D, Ruland J.

J Exp Med. 2009 Oct 26;206(11):2313-20. doi: 10.1084/jem.20091167. Epub 2009 Oct 19. Erratum in: J Exp Med. 2009 Nov 23;206(12):2851.

6.

Oncogenically active MYD88 mutations in human lymphoma.

Ngo VN, Young RM, Schmitz R, Jhavar S, Xiao W, Lim KH, Kohlhammer H, Xu W, Yang Y, Zhao H, Shaffer AL, Romesser P, Wright G, Powell J, Rosenwald A, Muller-Hermelink HK, Ott G, Gascoyne RD, Connors JM, Rimsza LM, Campo E, Jaffe ES, Delabie J, Smeland EB, Fisher RI, Braziel RM, Tubbs RR, Cook JR, Weisenburger DD, Chan WC, Staudt LM.

Nature. 2011 Feb 3;470(7332):115-9. doi: 10.1038/nature09671. Epub 2010 Dec 22.

7.

A catalytic-independent role for the LUBAC in NF-κB activation upon antigen receptor engagement and in lymphoma cells.

Dubois SM, Alexia C, Wu Y, Leclair HM, Leveau C, Schol E, Fest T, Tarte K, Chen ZJ, Gavard J, Bidère N.

Blood. 2014 Apr 3;123(14):2199-203. doi: 10.1182/blood-2013-05-504019. Epub 2014 Feb 4.

8.

Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma.

Davis RE, Ngo VN, Lenz G, Tolar P, Young RM, Romesser PB, Kohlhammer H, Lamy L, Zhao H, Yang Y, Xu W, Shaffer AL, Wright G, Xiao W, Powell J, Jiang JK, Thomas CJ, Rosenwald A, Ott G, Muller-Hermelink HK, Gascoyne RD, Connors JM, Johnson NA, Rimsza LM, Campo E, Jaffe ES, Wilson WH, Delabie J, Smeland EB, Fisher RI, Braziel RM, Tubbs RR, Cook JR, Weisenburger DD, Chan WC, Pierce SK, Staudt LM.

Nature. 2010 Jan 7;463(7277):88-92. doi: 10.1038/nature08638.

9.

NEMO-binding domain peptide inhibits constitutive NF-κB activity and reduces tumor burden in a canine model of relapsed, refractory diffuse large B-cell lymphoma.

Gaurnier-Hausser A, Patel R, Baldwin AS, May MJ, Mason NJ.

Clin Cancer Res. 2011 Jul 15;17(14):4661-71. doi: 10.1158/1078-0432.CCR-10-3310. Epub 2011 May 24.

10.

Critical role of PI3K signaling for NF-kappaB-dependent survival in a subset of activated B-cell-like diffuse large B-cell lymphoma cells.

Kloo B, Nagel D, Pfeifer M, Grau M, Düwel M, Vincendeau M, Dörken B, Lenz P, Lenz G, Krappmann D.

Proc Natl Acad Sci U S A. 2011 Jan 4;108(1):272-7. doi: 10.1073/pnas.1008969108. Epub 2010 Dec 20.

11.

Blockade of oncogenic IκB kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors.

Ceribelli M, Kelly PN, Shaffer AL, Wright GW, Xiao W, Yang Y, Mathews Griner LA, Guha R, Shinn P, Keller JM, Liu D, Patel PR, Ferrer M, Joshi S, Nerle S, Sandy P, Normant E, Thomas CJ, Staudt LM.

Proc Natl Acad Sci U S A. 2014 Aug 5;111(31):11365-70. doi: 10.1073/pnas.1411701111. Epub 2014 Jul 21.

12.

Constitutive BR3 receptor signaling in diffuse, large B-cell lymphomas stabilizes nuclear factor-κB-inducing kinase while activating both canonical and alternative nuclear factor-κB pathways.

Pham LV, Fu L, Tamayo AT, Bueso-Ramos C, Drakos E, Vega F, Medeiros LJ, Ford RJ.

Blood. 2011 Jan 6;117(1):200-10. doi: 10.1182/blood-2010-06-290437. Epub 2010 Oct 1.

13.

SHARPIN is a component of the NF-κB-activating linear ubiquitin chain assembly complex.

Tokunaga F, Nakagawa T, Nakahara M, Saeki Y, Taniguchi M, Sakata S, Tanaka K, Nakano H, Iwai K.

Nature. 2011 Mar 31;471(7340):633-6. doi: 10.1038/nature09815.

PMID:
21455180
14.
15.

Inhibition of proliferation and survival of diffuse large B-cell lymphoma cells by a small-molecule inhibitor of the ubiquitin-conjugating enzyme Ubc13-Uev1A.

Pulvino M, Liang Y, Oleksyn D, DeRan M, Van Pelt E, Shapiro J, Sanz I, Chen L, Zhao J.

Blood. 2012 Aug 23;120(8):1668-77. doi: 10.1182/blood-2012-02-406074. Epub 2012 Jul 12.

16.

Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling.

Lam LT, Davis RE, Pierce J, Hepperle M, Xu Y, Hottelet M, Nong Y, Wen D, Adams J, Dang L, Staudt LM.

Clin Cancer Res. 2005 Jan 1;11(1):28-40.

17.

Combinatorial BTK and MALT1 inhibition augments killing of CD79 mutant diffuse large B cell lymphoma.

Nagel D, Bognar M, Eitelhuber AC, Kutzner K, Vincendeau M, Krappmann D.

Oncotarget. 2015 Dec 8;6(39):42232-42. doi: 10.18632/oncotarget.6273.

18.

Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma.

Compagno M, Lim WK, Grunn A, Nandula SV, Brahmachary M, Shen Q, Bertoni F, Ponzoni M, Scandurra M, Califano A, Bhagat G, Chadburn A, Dalla-Favera R, Pasqualucci L.

Nature. 2009 Jun 4;459(7247):717-21. doi: 10.1038/nature07968. Epub 2009 May 3.

19.

IκB-ζ controls the constitutive NF-κB target gene network and survival of ABC DLBCL.

Nogai H, Wenzel SS, Hailfinger S, Grau M, Kaergel E, Seitz V, Wollert-Wulf B, Pfeifer M, Wolf A, Frick M, Dietze K, Madle H, Tzankov A, Hummel M, Dörken B, Scheidereit C, Janz M, Lenz P, Thome M, Lenz G.

Blood. 2013 Sep 26;122(13):2242-50. doi: 10.1182/blood-2013-06-508028. Epub 2013 Jul 18.

20.

Overexpression of heme oxygenase-1 induced by constitutively activated NF-κB as a potential therapeutic target for activated B-cell-like diffuse large B-cell lymphoma.

Huang J, Guo P, Ma D, Lin X, Fang Q, Wang J.

Int J Oncol. 2016 Jul;49(1):253-64. doi: 10.3892/ijo.2016.3529. Epub 2016 May 17.

PMID:
27211510

Supplemental Content

Support Center